Efficacious therapy for triple negative breast cancer (TNBC) continues to be a profound clinical challenge, but the key driven genes and convoluted signaling pathways are still unknown.
Background
Triple negative breast cancer (TNBC) is a common type of breast cancer (BC), which lacks expression of the estrogen, progesterone and human epidermal growth factor receptor 2 [1] . This subtype represents 12% to 17% of the breast cancers [2] . It often occurs in young women [3] , and it is more likely to recurrence and metastasize [4] . As this subtype lacks molecular targets, patients with TNBC cannot be treated with human epidermal growth factor receptor 2 (HER2)-targeted therapy or endocrine therapy. Currently, chemotherapy is the primary treatment for patients with TNBC [5] . Unfortunately, many tumors have significant drug resistance, and rapid recurrence and metastasis after neoadjuvant chemotherapy [6] . As of now, TNBC still has very limited treatment options and poor prognosis [7] . Therefore, it is necessary to further explore the potential therapeutic genes and novel targets of TNBC.
For the TNBC, we re-analyzed the gene expression profiles of GSE45827 [8] , GSE65194 [9] [10] [11] , GSE53752 [12] and GSE38959 [13] and determined the differentially expressed genes (DEGs) in 163 TNBC and 60 normal breast tissues samples. Bioinformatics analysis was used for functional enrichment analysis of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Next, we constructed a protein-protein interaction (PPI) network to filter hub genes related to TNBC and validation of hub gene expression levels by the Oncomine database. We performed a survival analysis of the hub gene by the Kaplan-Meier plotter database. We defined the DEGs, and enriched the biological functions and candidate genes, to provide new biomarkers of TNBC patients for early diagnosis and treatment.
Material and Methods

Data source
Data sets of our study were all from the Gene Expression Omnibus (GEO) public database (https://www.ncbi.nlm.nih. gov/geo/) and 4 sets of gene expression profiling chips (GEPC) are selected, including GSE38959 (GPL4133; Agilent-014850 Whole Human Genome Microarray 4 x 44 K G4112F), GSE53752 (GPL7264; Agilent-012097 Human 1A Microarray (V2) G4110B), GSE45827 and GSE65194 (GPL570; [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array).
Differentially expressed genes (DEGs)
The robust multi-array average (RMA) approach performed for background correction and normalization. The original GEO data were then converted into expression measures using the affy R package. Limma R package was subsequently employed for identifying differentially expressed genes (DEGs). We use P<0.05 and |logFC| >1 as data processing standards for analysis. We analyzed each data set and cross-screened differentially expressed genes using Venn 2.1 webtool (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
Gene symbol
Gene description Algorithms Probe ID Tumor  Total number   27006338  TNBC  GSE45827  GPL570  11  41  52   23144294  TNBC  GSE65194  GPL570  11  41  52   23049873  TNBC  GSE53752  GPL7264  25  51  76   23254957  TNBC  GSE38959  GPL4133  13  30  43   Table 2 . Statistical analysis of the 4 microarray databases.
GEO -Gene Expression Omnibus; TNBC -triple-negative breast cancer. 
ONCOMINE analysis
ONCOMINE is a publicly available genome-wide online cancer microarray database (https://www.oncomine.org/resource/login. html). In our study, we generated a P-value by Student's t-test in the TNBC group compared with the normal control group, which fold change was 2 and P-value was 0.01.
Survival analysis
In this study, overall survival and relapse-free survival rate was analyzed using samples from 1402 breast cancer patients and 3955 TNBC patients. We used the Kaplan-Meier plotter database (http://kmplot.com/analysis/index. php?p=service&cancer=breast) to assess the prognostic value of BC hub genes, especially in TNBC with estrogen (ER), progesterone (PR) and HER2 negative expression patients. Based on the only Jetset best probe set and the probe IDs for each gene are shown in Table 1 . Then, we divided the median values of each gene in each patient of TNBC into the 2 groups. P-value of <0.05 was considered statistically significant.
Results
Differentially expressed genes
In this study, we selected 4 GEPC (GSE45827, GSE53752, GSE38959, and GSE65194) from the GEO database. GSE45827 and GSE65194 included 41 TNBC and 11 healthy breast samples, GSE53752 contained 51 TNBC samples and 25 healthy breast samples and GSE38959 contained 30 TNBC and 13 healthy breast samples ( Table 2) . Volcano plots were generated to visualize the distribution of expressed genes between cancer and normal controls from different studies. Red or green dots in the plots represented significantly upregulated or downregulated genes respectively. Using the P<0.05 and |logFC| >1 as cutoff criterion, we recovered 4760, 3919, 1335,
DEGs Genes name
Upregulated CXCR4,IRAK1,GPSM2,CCNB1,CAPS,CCNE1,FOXM1,TOR3A,EN1,TTLL4,GNB4, KIF14,MAD2L1, TTC13, KIF4A, SQLE, MCM10, TYMS, MELK, HN1, NDC80, OIP5, CCNA2, HRASLS, MMP1, STMN1, CKS2, DEPDC1, BRI3BP, IDO1, LMNB1, SPAG5, CCNB2, PRC1, LRP8, CCNE2, MCM4, WISP1, CXCL10, CKAP2L, SULF1, CDCA2, RPP25, EXO1, HPSE, KDELR2,COL11A1, HIST1H1C, HORMAD1, NEK2,TMEM206, BAIAP2L1, C1orf106, ATP6V0B, EZH2, CHEK1, KIF11, TAP1, KIFC1, MASTL, VGLL1, ARNTL2, HIST2H2AA4, RRS1, PYCR1, KCNK1, CENPA, RNFT2, CDCA7, CENPN, BUB1, TNFRSF12A, OASL, TRIP13, CDC7, UBE2S, DDIT4, LYN, IFI6, MND1, SDC1, RRM2, HNRNPAB, TOP2A, FEN1, RAD54L, PKMYT1, LRRC59, KIF18A, FAM83D, CHAF1B, PPP1R14C, HDGF, COL5A1, PRAME, CTHRC1, UHRF1, CDKN2A, RECQL4, CDKN3, CENPM, FAM64A, CENPF, RANGAP1, CDCA8, TPX2, ANP32E, KPNA2, ANLN, BIRC5, LAMP3, KLRG2, RACGAP1, EZR, CDC6, APOBEC3B, AURKA, FN1, AURKB, CTSB, FANCA, TMEM79, SPP1, IL4I1, IMPA2, USP18, DHCR7, ZWINT, GTSE1, NUF2, PTTG1, CDCA5, UBE2T, BCL2A1, RGS1, TEAD4, PPP1CA, ECT2, MMP11, MYBL1, GGH, HMOX1, PARP12, PPP1R14B, TACC3, CLEC7A, DCBLD1, CFL1, CEP55, GZMB, MFAP2, DLGAP5, RAD51AP1, TBC1D7, MKI67, TMEM123, IL32, LYZ, NMU, GAPDH, SLC39A1, KIAA0101, HSD17B6,GINS2, DONSON, E2F8, TSTA3, S100P, HMGB3, HOMER3, FLVCR1, SLC39A7, C16orf59, ADAMDEC1, TMEM45A, IDH2, CXCL11, STK38L, OAS3, ZIC1, BLM, KIF2C, CCNYL1, TUBB3, PBK, S100A11, PHF5A, TK1, SHCBP1, ASPM, INHBA, ATAD2, BRIP1, IFI30, GJB2, ICAM1, CXCL9, SPC25, KIF15, HJURP, ATP6V1C2, RSAD2, RAD51, HMMR, ART3, KIF20A, SOX11, P4HB, CHAC2, TTK, NCAPG, NUSAP1 Downregulated KLHL13, IGF1, PPP1R14A, NAP1L2, FGFR1, NOSTRIN,NFIA, ARL4A, CNN1, MAOA, BCL2, MYBPC1, IRS1, BDH2, OXTR, TFAP2B, ZBTB20, HLF, DCX, LAMB3, PLSCR4, VIT, CMYA5, SEMA3G, PDGFD, FAM3B, NTN4, KIT, SCN4B, C1orf115, SH3BGRL2, HOXA5, RUNX1T1, WIF1, FMOD, SETBP1, MME, SCGB1D2, GPD1L, FOXO1, PDK4, CA12, BEND5, RERGL, CTTNBP2, GRAMD1C, NR3C2, SASH1,NTRK2, FTO, OLFM4, TCEAL7, PLAT, NBEA, ABCA6, C4orf32, PDGFA, MUCL1, APOD, CBX7, RAI2, SPATA18, LHFP, NME5, GNG11, RHOJ PGR, SRPX, NAV3, SSPN, AK5, ANKRD30A, GFRA1, CPE RSPO3, CX3CR1, ABCA5, TMTC1, CYBRD1, TFF1, SYNM,C2orf40,AMIGO2, AGR2, PTN, CXCL14, ITIH5, LGR6, AGR3, KIAA1683, DACH1, PTHLH, SLC40A1, CD36, DCLK1, TSHZ2, NR3C1, DNALI1, EDN3, EDNRB, MYH11, EGFLAM, SALL2, NRG2, RUNDC3B,GLI3,INHBB,SCGB2A1, HOXA7, DYNLRB2, PDE2A, ATP1A2, ACADSB, IGSF10, CDO1, SEPP1, SDPR, FOXA1, CXCL12,CX3CL1, COL14A1, SCGB2A2, ABAT, CAV1, TNS4, CCL28, JAM2, IRX2, HOXA4, DST, ITM2A, GPRASP1, C1orf226, FMO2, C3orf18, IL33, ME3, SCUBE2, PDZK1, CIRBP, CLDN8, PPP1R3C, STC2, THSD4, MAMDC2, TESC, ADAMTS5, AR, TFF3, SFRP1, SEMA3C, GRAMD3, NDN and 2791 the DEGs from GEO database GSE45827, GSE65194, GSE53752, and GSE38959 ( Figure 1A-1D ). Then, we screened 365 differentially expressed genes from 4 data sets through bioinformatics compared to normal breast tissues in the TNBC tissues ( Figure 1E ), including 153 downregulated genes and 212 upregulated genes (Table 3) .
Functional enrichment analyses
We used the DAVID online tool to perform GO and KEGG functional analysis of DEGs ( In addition, we found that KEGG pathway analysis of DEGs is mainly enriched in oocyte meiosis and cell cycle. The results are shown in Figure 2 .
PPI and hub gene
We enter the DEGs into STRING Version: 11.0 database to forecast PPI, and then the date of PPI network was refined using Cytoscape. After removing the isolated and partially connected nodes, the complex network of DEGs was established in Figure 3A . Evaluation of the top 10 genes by intersection of 12 algorithms with PPI networks (Table 1, Figure 3B-3M) . The results showed that the expression of MKI67, FOXM1, GAPDH, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10 had marked differences among different datasets in BC (Figure 4 ).
ONCOMINE analysis of hub genes
To detect the expression of hub genes, we researched that revealed hub genes mRNA expression levels of BC were significantly higher than healthy tissue samples by Oncomine analysis datasets of different cancer types ( Figure 5 ).
Survival analysis
We evaluated hub genes using the Kaplan-Meier plotter tool for analysis of overall survival and relapse-free survival in 1402 BC patients. Simultaneously, we detected that high expression of KIT, IGF1 ICAM1, low expression of MKI67, FOXM1, GADPH, and CCNB2 hub gene contributes to overall survival in BC patients. These hub genes (MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, and ICAM1) were closely related to overall survival of BC patients. However, no significant difference was found in the CDKN2A, CXCR4, and CXCL10 of hub genes for overall survival analysis ( Figure 6 ). The rank for a gene is the median rank for that gene across each of the abalyses. The p.Value for a gene is its p. Value for the median ranked analysis. 
Discussion
TNBC is the primary subtype of BC with poor prognosis and lack of valid therapeutic targets. Because of the lack of useful therapeutic targets, TNBC patients cannot benefit from endocrine therapy or HER2 targeted therapy, so chemotherapy is the primary adjunct therapy. However, TNBC patients are more susceptible to drug resistance. So, it is necessary to find new specific targets for TNBC patients.
Based on public databases for gene expression and PPI analysis, we identified potential critical genes associated with TNBC. Then, we screened DEGs with normal breast tissue from the GEO database. Among them, we screened 212 upregulated genes and 153 downregulated DEGs associated with GO terms including cell division, mitotic nuclear division, extracellular space, nucleus, midbody, protein binding, and microtubule motor activity, and mainly enriched in the KEGG terms cell cycle and oocyte meiosis. We constructed the PPI network using differentially expressed genes and screened 10 hub genes by the intersection of 12 algorithms, including MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10. Among MKI67, FOXM1, GAPDH, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10 were significantly upregulated in TNBC. Finally, we used the Kaplan-Meier plotter tool to predict the prognosis of hub genes in patients with TNBC.
Through the Kaplan-Meier plotter online public tool, overexpression of MKI67, FOXM1, GAPDH, and CCNB2 were associated with unfavorable prognosis in BC patients, no significant difference was found in the CDKN2A, CXCR4, and CXCL10 of hub genes for overall survival analysis ( Figure 6 ). We found that overexpression of CXCR4 and CXCL10 were related to the favorable prognostic factor of TNBC patients (Figure 7) . CXCR4, CXC motif chemokine receptor type 4, is involved in either normal (maintaining stemness [14] or inducing differentiation [15] ) or abnormal (developing cancer [16] and other pathologies [17] ) events. CXCL10, CXC motif chemokine ligand 10, may accelerate cancer growth in nonimmune cell types and orchestrate an antitumor response [18] . CXCR4 has been associated with several diseases, including human immunodeficiency virus (HIV) infection [19] , cancers [17] , and warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome [20] . Some research has demonstrated that CXCR4 can be developed to treat these diseases, especially related to the prognosis of cancers such as colorectal cancer [21, 22] , thyroid carcinoma [23] , head and neck squamous cell carcinomas [24] , and breast cancer [25] . It was reported that the inhibitors of CXCR4 could benefit to TNBC patients [26] , but some reports showed that it could not benefit to triple-negative breast cancer patients [27] . Thus, the role of CXCR4 needs further study.
It has been reported that CXCL10 might be related to the prognosis in pancreatic adenocarcinoma [28] and TNBC [29] . Our research showed that CXCR4 and CXCL10 overexpression could be related to the prognosis of malignant diseases. For TNBC, our studies demonstrated that CXCR4 and CXCL10 were the chemokines related to prognosis. Therefore, CXCR4 and CXCL10 might be an effective prognostic factor and obviously potential therapeutic target for TNBC treatment.
In addition to CXCR4 and CXCL10, the remaining 8 hub genes were the MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, and ICAM1. We found that these genes had no significant difference for TNBC analysis. This result was consistent with the Oncomine database. However, the mechanism of these hub genes is not fully understood in TNBC and needs further study.
Conclusions
Bioinformatics identified 365 differentially expressed genes from the GEO database.
Among them, TNBC-related 10 hub genes including MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10. All of them upregulated in TNBC except for KIT and IGF1. We found that overexpression of CXCR4 and CXCL10 were the favorable prognostic factor in relapse-free survival in TNBC. 
